Comment in

• The Use of Pediatric Extrapolation to Avoid Unnecessary Pediatric Clinical Trials.

  Nelson RM. Nelson RM. Am J Bioeth. 2020 May;20(4):114-116. doi: 10.1080/15265161.2020.1730489. Am J Bioeth. 2020. PMID: 32208075 No abstract available.
• When Higher Risk Does Not Equal Greater Harm: Doing the Most Good in a Limited Pediatric Study Population.

  Matsler J, Young JM. Matsler J, et al. Am J Bioeth. 2020 May;20(4):118-120. doi: 10.1080/15265161.2020.1730491. Am J Bioeth. 2020. PMID: 32208078 No abstract available.
• Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Pediatric Conditions.

  Porter KM, Stevens A, Wilfond BS. Porter KM, et al. Am J Bioeth. 2020 May;20(4):116-118. doi: 10.1080/15265161.2020.1730494. Am J Bioeth. 2020. PMID: 32208080 Free PMC article. No abstract available.
• Balancing Risk and Reward: Greater Research Oversight Is Appropriate for Novel Therapies for Children With Life-Limiting Illness.

  Unguru Y. Unguru Y. Am J Bioeth. 2020 May;20(4):104-105. doi: 10.1080/15265161.2020.1730484. Am J Bioeth. 2020. PMID: 32223620 No abstract available.
• Bringing Known Drugs to Pediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal Risk.

  Sharma A, Johnson LM. Sharma A, et al. Am J Bioeth. 2020 May;20(4):106-108. doi: 10.1080/15265161.2020.1730485. Am J Bioeth. 2020. PMID: 32223621 No abstract available.
• Balancing Scientific Progress With Pediatric Protections: No Direct Benefit Now, But Potential Novel Therapy in the Future.

  Lee SW, Ginsberg JC. Lee SW, et al. Am J Bioeth. 2020 May;20(4):108-110. doi: 10.1080/15265161.2020.1730486. Am J Bioeth. 2020. PMID: 32223623 No abstract available.